JP2006516113A - 血栓溶解および抗凝固両方の機能を有する融合タンパク質、ならびにその使用 - Google Patents

血栓溶解および抗凝固両方の機能を有する融合タンパク質、ならびにその使用 Download PDF

Info

Publication number
JP2006516113A
JP2006516113A JP2004533177A JP2004533177A JP2006516113A JP 2006516113 A JP2006516113 A JP 2006516113A JP 2004533177 A JP2004533177 A JP 2004533177A JP 2004533177 A JP2004533177 A JP 2004533177A JP 2006516113 A JP2006516113 A JP 2006516113A
Authority
JP
Japan
Prior art keywords
fusion protein
protein
thrombolytic
anticoagulant
hirudin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004533177A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006516113A5 (cg-RX-API-DMAC10.html
Inventor
炳興 石
祖澤 呉
愛平 于
春娜 董
Original Assignee
中華人民解放軍軍事医学科学院放射医学研究所
北京魯銀利華医薬科技発展有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中華人民解放軍軍事医学科学院放射医学研究所, 北京魯銀利華医薬科技発展有限公司 filed Critical 中華人民解放軍軍事医学科学院放射医学研究所
Publication of JP2006516113A publication Critical patent/JP2006516113A/ja
Publication of JP2006516113A5 publication Critical patent/JP2006516113A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2004533177A 2002-09-03 2003-09-03 血栓溶解および抗凝固両方の機能を有する融合タンパク質、ならびにその使用 Pending JP2006516113A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNA021290865A CN1480466A (zh) 2002-09-03 2002-09-03 一类溶栓抗凝双功能融合蛋白及应用
PCT/CN2003/000743 WO2004022598A1 (fr) 2002-09-03 2003-09-03 Proteine hybride assurant les fonctions d'hemolyse et d'anticoagulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010106629A Division JP2010184930A (ja) 2002-09-03 2010-05-06 血栓溶解および抗凝固両方の機能を有する融合タンパク質、ならびにその使用

Publications (2)

Publication Number Publication Date
JP2006516113A true JP2006516113A (ja) 2006-06-22
JP2006516113A5 JP2006516113A5 (cg-RX-API-DMAC10.html) 2006-12-07

Family

ID=31954566

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004533177A Pending JP2006516113A (ja) 2002-09-03 2003-09-03 血栓溶解および抗凝固両方の機能を有する融合タンパク質、ならびにその使用
JP2010106629A Pending JP2010184930A (ja) 2002-09-03 2010-05-06 血栓溶解および抗凝固両方の機能を有する融合タンパク質、ならびにその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010106629A Pending JP2010184930A (ja) 2002-09-03 2010-05-06 血栓溶解および抗凝固両方の機能を有する融合タンパク質、ならびにその使用

Country Status (8)

Country Link
US (1) US8212003B2 (cg-RX-API-DMAC10.html)
EP (1) EP1541589B1 (cg-RX-API-DMAC10.html)
JP (2) JP2006516113A (cg-RX-API-DMAC10.html)
CN (2) CN1480466A (cg-RX-API-DMAC10.html)
AT (1) ATE376001T1 (cg-RX-API-DMAC10.html)
AU (1) AU2003261606A1 (cg-RX-API-DMAC10.html)
DE (1) DE60316967T2 (cg-RX-API-DMAC10.html)
WO (1) WO2004022598A1 (cg-RX-API-DMAC10.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010512349A (ja) * 2006-12-15 2010-04-22 インスティテュート オブ ラジエーション メディシン,アカデミー オブ ミリタリー メディカル サイエンシズ,ピーエルエー 低出血性抗凝固性融合タンパク質の調製および使用
JP2013535211A (ja) * 2010-08-05 2013-09-12 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ 血栓溶解及び抗凝固特性を有するタンパク質融合構築物
JP2015533483A (ja) * 2012-09-07 2015-11-26 サノフイ メタボリックシンドロームを治療するための融合タンパク質
KR20230057075A (ko) * 2021-10-21 2023-04-28 중앙대학교 산학협력단 트롬빈 검출용 신규한 펩타이드 및 이의 용도

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102443065A (zh) * 2005-06-01 2012-05-09 中国人民解放军军事医学科学院放射与辐射医学研究所 特异性抗凝血物质的制备及其应用
CN1896108B (zh) * 2005-06-01 2012-01-04 中国人民解放军军事医学科学院放射与辐射医学研究所 特异性抗凝血物质的制备及其应用
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
WO2007132481A2 (en) * 2006-05-12 2007-11-22 Bharat Biotech International Limited Novel thrombolytic molecules and a process therefor
CN100519585C (zh) * 2007-02-06 2009-07-29 中国人民解放军军事医学科学院基础医学研究所 P11与sak的融合蛋白及其制备方法和用途
DK2109457T3 (en) * 2007-02-12 2016-04-11 Csl Behring Gmbh THERAPEUTIC USE OF KAZAL TYPE SERINE PROTEASE INHIBITORS
KR102069498B1 (ko) * 2007-09-28 2020-01-23 포톨라 파마슈티컬스, 인코포레이티드 인자 Xa 저해제에 대한 안티도트 및 그것을 사용하는 방법
DE102009010611A1 (de) * 2009-02-25 2010-08-26 Siemens Aktiengesellschaft Vorrichtung und Verfahren zur Steuerung einer mit mehreren Brennern ausgestatteten Turbine für flüssige oder gasförmige Brennstoffe
CN102180973B (zh) * 2011-03-18 2012-08-29 重庆大学 靶向多功能防栓融合蛋白及其制备方法和应用
CN106366200B (zh) * 2015-07-23 2020-04-10 武汉光谷人福生物医药有限公司 制备重组葡激酶-水蛭素融合蛋白的方法
JP7028904B2 (ja) * 2019-03-21 2022-03-02 アカデミア シニカ 合成ペプチド、それを備える薬学的組成物及び血栓塞栓症関連疾患の治療におけるその使用
CN113150168B (zh) * 2021-01-29 2022-11-11 武汉真福医药股份有限公司 一种qk纤溶酶基因-水蛭素融合蛋白的制备方法及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
GB8927722D0 (en) * 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
US5759542A (en) * 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US6015787A (en) * 1997-11-04 2000-01-18 New England Medical Center Hospitals, Inc. Cell-permeable protein inhibitors of calpain
US6423680B1 (en) * 1998-10-30 2002-07-23 Hsc Research And Development Limited Partnership Inhibitor of platelet activating factor
CN1188522C (zh) * 2001-07-20 2005-02-09 健力福生化技术(上海)有限公司 一种血栓靶向性溶栓蛋白表达质粒及其构建
CN1181099C (zh) * 2002-07-23 2004-12-22 中国人民解放军第二军医大学 兼抗凝溶栓双重功能的血栓靶向融合蛋白mA5UKB

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010512349A (ja) * 2006-12-15 2010-04-22 インスティテュート オブ ラジエーション メディシン,アカデミー オブ ミリタリー メディカル サイエンシズ,ピーエルエー 低出血性抗凝固性融合タンパク質の調製および使用
JP2013535211A (ja) * 2010-08-05 2013-09-12 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ 血栓溶解及び抗凝固特性を有するタンパク質融合構築物
JP2015533483A (ja) * 2012-09-07 2015-11-26 サノフイ メタボリックシンドロームを治療するための融合タンパク質
KR20230057075A (ko) * 2021-10-21 2023-04-28 중앙대학교 산학협력단 트롬빈 검출용 신규한 펩타이드 및 이의 용도
KR102789819B1 (ko) 2021-10-21 2025-03-31 중앙대학교 산학협력단 트롬빈 검출용 신규한 펩타이드 및 이의 용도

Also Published As

Publication number Publication date
AU2003261606A1 (en) 2004-03-29
EP1541589A1 (en) 2005-06-15
EP1541589B1 (en) 2007-10-17
CN1678636A (zh) 2005-10-05
DE60316967D1 (de) 2007-11-29
CN1480466A (zh) 2004-03-10
DE60316967T2 (de) 2008-05-08
JP2010184930A (ja) 2010-08-26
CN1301268C (zh) 2007-02-21
US8212003B2 (en) 2012-07-03
WO2004022598A1 (fr) 2004-03-18
US20060127389A1 (en) 2006-06-15
EP1541589A4 (en) 2005-11-16
ATE376001T1 (de) 2007-11-15

Similar Documents

Publication Publication Date Title
JP2010184930A (ja) 血栓溶解および抗凝固両方の機能を有する融合タンパク質、ならびにその使用
US5759542A (en) Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
JP4250660B2 (ja) 活性化されたミクロプラスミンの産生方法
JP3189052B2 (ja) 抗血液凝固活性を有するポリペプチド
JP2010189405A (ja) 修飾されたアネキシン蛋白質および血栓症を防ぐための方法
JP2007195558A6 (ja) 活性化されたミクロプラスミンの産生方法
JP2002502421A (ja) 血栓障害の処置方法
JPWO1992000325A1 (ja) 抗血液凝固活性を有するポリペプチド
WO1994015953A1 (en) Platelet-specific therapeutic compound and method of treating platelet-mobilizing diseases
JP2006516113A5 (cg-RX-API-DMAC10.html)
JPH0193535A (ja) 線溶活性増強剤
EP0668875A1 (en) Clot directed anticoagulant, process for making same and methods of use
JP5345069B2 (ja) 低出血性抗凝固性融合タンパク質の調製および使用
EP0099126B1 (en) Thrombolytic composition
JPS6360938A (ja) 修飾組織型プラスミノ−ゲン活性化因子およびその製造方法
RO116969B1 (ro) Derivati de stafilokinaza, procedeu pentru prepararea acestora si compozitie farmaceutica care ii contine
JP2002528058A (ja) コントートロスタチン(cn)、並びに転移及び他の症状の抑制におけるその使用方法
JPH09504554A (ja) 血栓形成を阻止する方法及び組成物
JPH07291999A (ja) 血小板安定化因子ix−フラグメント、その製造方法及びこれを含有する薬剤
JP2904893B2 (ja) 医薬製剤
WO1992018139A1 (en) Chimeric molecule with plasminogen activator activity and affinity for atherosclerotic plaques
JPH04505698A (ja) ヒトフィブロネクチンポリペプチド類似体のクローニング及び製造並びにこのようなポリペプチド類似体の使用法
CN116688099A (zh) 一种预防和/或治疗血栓疾病的联合用药物和应用
Yan et al. Design and characterization of a platelet‐targeted plasminogen activator with enhanced thrombolytic and antithrombotic potency
JPH0327286A (ja) 組織プラスミノーゲン活性化因子の誘導体

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061013

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090714

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091009

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091116

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100518